2curex to launch first product without first meeting with doctors
When 2curex sends its assistive product for cancer treatment identification to the European market in a few weeks, the launch will be abnormal due to the Covid-19 pandemic having led to congress cancellations throughout the world.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
14 years of work will cumulate in less than one month for Danish biotech company 2curex when its sends its first product, Inditreat, used cancer diagnostics, to the European market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Cancer firms collaborate over breast cancer treatment
For abonnenter
